Three weeks of low-dose rituximab was found to prevent relapses and disability progression in NMOSD patients, without serious side effects.| Neuromyelitis News
Many MS patients experience primary headaches, and disease-modifying therapies may play different roles in their development, per a study.| Multiple Sclerosis News Today